Study of tiny blood particles in heart amyloidosis
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at tiny particles called extracellular vesicles in the blood of people with a specific type of heart amyloidosis. It aims to find better ways to track the disease and predict outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have been diagnosed with transthyretin cardiac amyloidosis (a heart condition caused by abnormal protein buildup).
- You are willing to follow the study's rules and attend all necessary visits.
- You can understand and sign a consent form.
- You do not have other serious heart problems like severe blocked arteries or major valve disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This study aims to find, describe, and track people with cardiac amyloidosis over time. It uses MRI scans and other tests to better understand the condition, which may help guide future treatment.
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
This research study checks a small sample of heart tissue during pacemaker or defibrillator placement to see if amyloidosis, a condition where abnormal proteins build up in organs, is present. It aims to find amyloidosis earlier so treatment can start sooner.
This study looks at how the liver and blood clotting are affected in people with a type of heart disease called transthyretin amyloidosis. It may help doctors better understand and manage this condition.
Hear when a new Amyloidosis, Hereditary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.